Created date

Published on

You are here:

MS in the media - 14 October 2016

8 - 14 October 2016

These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts

How people with MS feel about risk

A US study used a measure called the Risk Propensity Scale and found that people with MS were risk neutral - neither cautious nor inclined to take risks.  Using a scenario about a hypothetical drug that was effective but potentially fatal, participants were found to be inclined not to take risks.  The results contrast with previous work that showed people with MS were more inclined than their health professionals to accept potential risks with treatment

Source: MD Magazine

MS Trust link: Weighing up the pros and cons of treatment

Stress and onset of symptoms

Australian research looked for the effects of stress in the year before people experienced a first demyelinating event (first symptoms that might lead to a diagnosis of MS).  They found that serious illness doubled the chance of a first demyelinating event, and personal injury or illness of self, a close family member or a friend increased the risk by one and a half times

Source: MS Research Australia

MS Trust link: Stress

Lemtrada (alemtuzumab) and disability improvement

A new analysis of trial data found that about a quarter (28%) of people taking Lemtrada showed at least a one point improvement in disability measures over two years.  In a control group taking Rebif the improvement was seen in 15%.  The Lemtrada group was more likely to show improvements in cognitive symptoms and ataxia

Source: Medical News Today
Source: MedPage Today

MS Trust link: Lemtrada (alemtuzumab)

Stress incontinence in women with MS

French research found that about a third of women with MS have stress incontinence.  The risk highest in younger mothers with relapsing remitting MS.  As the article suggests that 17% to 41% of women in the general population have stress incontinence, the results are hard to interpret.

Source: MS News Today

MS Trust link: Bladder symptoms

Factors indicating how MS may develop

Canadian research looked at how people's MS had developed eight years after they had been involved in a beta interferon study.  They found that higher brain volume at the start was an indicator of a slower MS course, whilst increases in EDSS in the first two years suggested a worse outcome.  People who had been on beta interferon the longest tended to do better

Source: MD Magazine

MS Trust link: Prognosis

Low dose naltrexone safety study

A study looking at people who took only low dose naltrexone (LDN) or Copaxone with or without LDN found that scores for timed walk tests, MRI data and liver enzyme levels were similar.  The study was looking at whether LDN is safe in the long-term rather than efficacy

Source: MD Magazine

MS Trust link: Low dose naltrexone (LDN)

Intimate relations

Australian research (originally published in April) found that people who felt better about themselves and who had come to terms with their diagnosis scored higher on measures of 'intimate relationship quality'. 

Source: MS Research Australia

MS Trust link: Talking about sexual problems